Log in

Relevant bibliographies by topics / Cell-based immunotherapy / Books

To see the other types of publications on this topic, follow the link: Cell-based immunotherapy.

Books on the topic 'Cell-based immunotherapy'

Author: Grafiati

Published: 7 December 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 15 books for your research on the topic 'Cell-based immunotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

García-Olmo, Damián. Cell therapy. Edited by García-Verdugo José Manuel. New York: McGraw-Hill Interamerica, 2008.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kang, Chʻang-yul. Pairŏsŭ pektʻŏ ro hyŏngjil toiptoen hangwŏn chesi sepʻo ŭi myŏnyŏk chʻiryoje yuhyosŏng pʻyŏngka mit sihŏmpŏp yŏnʼgu =: Development and estimation of immunotherapeutic cell-based vaccine approaches using antigen presenting cells transduced with viral vector. [Seoul]: Sikpʻum Ŭiyakpʻum Anjŏnchʻŏng, 2007.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

3

Cell-Based Cancer Immunotherapy. Elsevier Science & Technology Books, 2024.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

4

Borrego, Francisco, Susana Larrucea, Rafael Solana, and Raquel Tarazona, eds. NK Cell-Based Cancer Immunotherapy. Frontiers Media SA, 2016. http://dx.doi.org/10.3389/978-2-88919-934-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Santich, Brian H., Nai-Kong Cheung, and Christian Klein, eds. Bispecific Antibodies for T-Cell Based Immunotherapy. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88966-415-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Dal Col, Jessica, Alejandro López-Soto, and Riccardo Dolcetti, eds. Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88963-726-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Ascierto, Paolo A., David F. Stroncek, and Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana, 2019.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

8

Ascierto, Paolo A., David F. Stroncek, and Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ascierto, Paolo A., David F. Stroncek, and Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana Press, 2015.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

10

Barisa, Marta. ?dT Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation. Elsevier Science & Technology Books, 2024.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

11

Barisa, Marta. ?dT Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation. Elsevier Science & Technology, 2024.

Find full text

APA, Harvard, Vancouver, ISO, and other styles

12

Cifaldi, Loredana, Daniel Olive, and James Di Santo, eds. Molecular Strategies Aimed to Boost NK Cell-based Immunotherapy of Cancer. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88963-876-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Farghaly, Samir A. Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0005.

Full text

Abstract:

The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficacy of adoptive cell therapy (ACT) in EOC. The aim of this chapter is to present an overview of ACT in EOC, focusing on Human Leukocyte Antigen (HLA)-restricted tumor infiltrating lymphocytes and MHC-independent immune effectors such as natural killer and cytokine-induced killer. The available data suggest that ACT may provide the best outcome in patients with low tumor burden, minimal residual disease, or maintenance therapy. Further preclinical studies and clinical trials are needed.

APA, Harvard, Vancouver, ISO, and other styles

14

Alharbi, Yousef, Manish S. Patankar, and Rebecca J. Whelan. Antibody-Based Therapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0006.

Full text

Abstract:

With their role in connecting disease-associated antigens to the cellular immune response, antibodies hold considerable promise as therapeutic agents. This chapter discusses three classes of therapeutic antibodies that have been developed for use in ovarian cancer therapy. The first includes antibodies selected against tumor-associated antigens such as MUC16/CA125, mesothelin, epithelial cell adhesion molecule, and folate receptor α‎. Antibodies in the second class target proteins such as CTLA-4 and PD1 that act as immune response checkpoint receptors. The third class of antibodies target secreted factors that promote tumor growth: targets in this class include vascular endothelial growth factor, cytokines, and chemokines. The development of each of these is described. The chapter also discusses the complications presented by soluble antigens, which serve to limit the applicability of antigens (such as MUC16/CA125) that are both cell-surface associated and circulating and the prospects for the combination of antibody-based immunotherapy and chemotherapy.

APA, Harvard, Vancouver, ISO, and other styles

15

Abe, Hiroyuki, Amane Sasada, Shigeki Tabata, and Minako Abe. Heat Shock Protein Vaccine Therapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0009.

Full text

Abstract:

Despite advances in chemotherapeutic regimens, ovarian cancer has a poor prognosis. Therefore important effective treatments are urgently needed. Many studies have reported that the immune system plays a critical role in disease progression and overall survival. One known effective immunotherapy is the dendritic cell (DC)-based vaccine pulsed with tumor-associated antigens. This chapter reports on a method of production of a novel DC-based vaccine. The key technologies are (a) monocyte collection without leukapheresis, (b) monocyte expansion, (c) production of dendritic cells, (d) multiple overlapping long peptides with heat shock protein 70, and (e) combination immunotherapy approach. The next generation of immunotherapy for ovarian cancer will be focused on combination approaches that simultaneously augment immunity while preventing local immune suppression. Possible combinations which might be useful to help patients with ovarian cancer are summarized in this chapter.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!